Abstracts selected for oral and poster
presentation
TORONTO and CAMBRIDGE, MA,
July 10, 2019 /CNW/ - ProMIS
Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology
company focused on the discovery and development of antibody
therapeutics targeting toxic oligomers implicated in the
development of neurodegenerative diseases, will give an oral
presentation on its lead clinical candidate, PMN310 for Alzheimer's
disease, at the annual Alzheimer's Association International
Conference® (AAIC), which occurs July 14-18. A second poster presentation
focuses on the behavior of misfolded TDP43 involved in the
development of neurological disorders such as amyotrophic lateral
sclerosis (ALS) and frontotemporal dementia.
AAIC® is the largest, most influential
international meeting focused on advancing dementia science. The
annual conference convenes the world's leading basic science and
clinical researchers, next-generation investigators, clinicians and
the care research community to share research discoveries
supporting new methods of prevention, treatment and diagnosis of
Alzheimer's disease.
ProMIS' Chief Development Officer Dr. Johanne Kaplan will deliver the oral
presentation, "Selective Targeting of Amyloid-Beta Oligomer Species
By PMN310, a Monoclonal Antibody Rationally Designed for Greater
Therapeutic Potency in Alzheimer's Disease," on Thursday, July 18, 2019 from 11:45 AM – 12:00 PM
in Concourse Hall 151. Dr. Kaplan's slide presentation will be
available on the company's website immediately following the
presentation.
ProMIS' Chief Science Officer Dr. Neil
Cashman will deliver the poster (#33496), "The Pathological
Interactome of Tdp-43 Includes Human Wildtype SOD1" on Wednesday, July 17, 2019 in South Hall GH.
The conference takes place at the Los
Angeles Convention Center. For more information, visit
www.alz.org/aaic.
About the ProMIS Pipeline
ProMIS Neurosciences' lead
candidate, PMN310, is a monoclonal antibody for Alzheimer's disease
created with the ProMIS drug discovery and development platform, a
novel, proprietary method for discovering and developing antibodies
that can uniquely and precisely target toxic forms of otherwise
normal proteins. PMN310 selectively targets the toxic oligomeric
species of amyloid beta (Aß), a root cause of Alzheimer's disease.
Preclinical studies show PMN310 demonstrates a high degree of
binding to toxic oligomers without binding to non-toxic forms of
amyloid beta protein and greater selectivity versus other
Aß-directed antibodies. ProMIS has developed antibody candidates
that demonstrate high selectivity for the toxic species of
naturally occurring proteins in the brain, including other antibody
candidates for Alzheimer's disease that selectively target toxic
Tau, antibody candidates for Parkinson's disease that show
best-in-class selectivity for toxic forms of alpha-synuclein, and
antibody candidates for ALS that target the toxic form of
TDP43.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc.
is a development stage biotechnology company focused on discovering
and developing antibody therapeutics selectively targeting toxic
oligomers implicated in the development and progression of
neurodegenerative diseases, in particular Alzheimer's disease (AD),
amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).
The Company's proprietary target discovery platform is based on the
use of two complementary thermodynamic, computational discovery
engines - ProMIS and Collective Coordinates - to predict novel
targets known as Disease Specific Epitopes on the molecular surface
of misfolded proteins. Using this unique precision approach, the
Company is developing novel antibody therapeutics for AD, ALS and
PD. ProMIS is headquartered in Toronto,
Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on
the Toronto Stock Exchange under the symbol PMN, and on the OTCQB
Venture Market under the symbol ARFXF.
To learn more, visit us at www.promisneurosciences.com, follow
us on Twitter and LinkedIn and listen to the podcast, Saving
Minds, at iTunes or Spotify.
The TSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This information
release contains certain forward-looking information. Such
information involves known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-to-present-data-at-2019-alzheimers-association-international-conference-300881024.html
SOURCE ProMIS Neurosciences Inc.